Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro HanawaTakeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Research output: Contribution to journalComment/debate

Abstract

The HTML version of this Article contained errors in Supplementary Figure S2 “Flowchart of the lyso-Gb3 screening and gene analysis in female patients”, which have been detailed in the associated Correction.

Original languageEnglish
Number of pages1
JournalGenetics in Medicine
Volume21
Issue number5
DOIs
Publication statusPublished - May 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Maruyama, H., Miyata, K., Mikame, M., Taguchi, A., Guili, C., Shimura, M., Murayama, K., Inoue, T., Yamamoto, S., Sugimura, K., Tamita, K., Kawasaki, T., Kajihara, J., Onishi, A., Sugiyama, H., Sakai, T., Murata, I., Oda, T., Toyoda, S., ... Ishii, S. (2019). Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31). Genetics in Medicine, 21(5). https://doi.org/10.1038/s41436-019-0447-8